---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic burden and healthcare resource utilization. Topics: Drug patterns and economic costs, Healthcare costs and resource utilization before and after starting long-term prophylaxis: US commercial claims, Healthcare costs with lanadelumab compared with berotralstat: US claims, Treatment costs over time with lanadelumab: US claims, and 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Drug patterns and economic costs

> “Notably, annualized expenditures for ODT prescriptions, hospitalizations, and ED visits averaged >$200,000, even after initiation of SC LTP.”

Source: [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/)

<a id="topic-2.2.1.8.2-2"></a>

### Healthcare costs and resource utilization before and after starting long-term prophylaxis: US commercial claims

> “A total of 328 patients were included in this analysis.”
> “Most patients (67%) had ≥1 post-index on-demand therapy claim.”
> “During follow-up, 17% and 8% had ≥1 HAE-related ER and inpatient visit, respectively.”
> “Mean annualized total HAE-related healthcare costs per patient were $165,348 pre-LTP and $515,333 post-LTP, driven by increased LTP pharmacy costs (mean $395,845 PPPY) and partially offset by reductions in medical costs (ER/inpatient, mean $8344 PPPY).”
> “This study found that 55% of patients had refill gaps in LTP claims, discontinued, or switched LTP within a year of initiation.”

Source: [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/)

<a id="topic-2.2.1.8.2-3"></a>

### Healthcare costs with lanadelumab compared with berotralstat: US claims

> “Fifty-seven lanadelumab- and 32 berotralstat-treated patients were included.”
> “Total HAE treatment costs were similar during months 0–6 (lanadelumab, $377,326 vs berotralstat, $373,010), but decreased in months 7–12 ($319,967) and 13–18 ($283,241) of lanadelumab.”
> “On-demand treatment/short-term prophylaxis costs were lower for lanadelumab across the three follow-up periods than for berotralstat during months 0–6 (berotralstat, $60,451; lanadelumab, months 0–6, $46,336, months 7–12, $37,578, months 13–18, $23,968).”
> “all dollar estimates were inflated to 2022 dollars using the medical care component of the Consumer Price Index.”

Source: [Princic et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11963383/)

<a id="topic-2.2.1.8.2-4"></a>

### Treatment costs over time with lanadelumab: US claims

> “Fifty-four lanadelumab users were included; 25 (46%) had evidence of down titration.”
> “Lanadelumab costs decreased from $316,724 to $269,861 to $246,919 in months 0-6, 7-12, and 13-18, respectively (p < .01); total HAE treatment costs decreased from $377,076 to $329,855 to $286,074 in months 0-6, 7-12, and 13-18, respectively (p < .01).”

Source: [Shah et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37395381/)

<a id="topic-2.2.1.8.2-5"></a>

### Direct and indirect costs of on-demand treatment alone: US patient survey

> “Per patient/year direct costs associated with modeled on-demand–only treatment totaled $363,795, with additional indirect socioeconomic costs of $52,576 per patient/year.”
> “Medications comprise the largest component (62.5%) of modeled on-demand–only treatment, at an estimated $227,674 per patient per year.”
> “The second highest component cost was hospitalization for treatment of an HAE attack (22.1%), followed by ED visits (12.5%).”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-2.2.1.8.2-6"></a>

### Annual per-patient costs by attack severity before current prophylactic agents: US patient survey

> “Total annual per-patient costs are estimated at $42,000 for the average HAE patient, with costs totaling $14,000 for patients with mild attacks, $27,000 for patients with moderate attacks, and $96,000 for patients with severe attacks.”
> “Hospital costs account for 67% of direct medical costs.”
> “Respondents reported high rates of missed work, lost productivity, and lost income, contributing to indirect costs totaling $16,000 annually for the average patient.”

Source: [Wilson et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20408341/)

<a id="topic-2.2.1.8.2-7"></a>

### Resource use after insurance delays or denials of prophylaxis

> “A total of 70% of participants reported an increased frequency of angioedema attacks resulting from insurance delays or denials.”
> “Twenty-five percent of respondents reported more urgent care or emergency department visits.”

Source: [Arora et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37558360/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
